Real-World Outcomes in Metastatic HR+/HER2-, HER2+ and Triple Negative Breast Cancer after Start of First-Line Therapy

References

• Siegel RL , MillerKD, FuchsHE, JemalA. Cancer statistics, 2022. CA Cancer J. Clin.72(1), 7–33 (2022).
   PubMed Web of Science ®Google Scholar
• Saad ED , KatzA, BuyseM. Overall survival and post-progression survival in advanced breast cancer: a review of recent randomized clinical trials. J. Clin. Oncol.28(11), 1958–1962 (2010).
   PubMed Web of Science ®Google Scholar
• La Verde N , CollovaE, BlasiLet al. Overall survival in metastatic breast cancer patients in the third millennium: results of the COSMO study. Clin Breast Cancer21(5), e489–e496 (2021).
   PubMed Web of Science ®Google Scholar
• Cardoso F , SenkusE, CostaAet al. 4th ESO-ESMO International Consensus Guidelines for advanced breast cancer (ABC 4) dagger. Ann. Oncol.29(8), 1634–1657 (2018).
   PubMed Web of Science ®Google Scholar
• Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Breast Cancer V.4.2022. © National Comprehensive Cancer Network, Inc (2022). All rights reserved. Accessed [12August2022]. To view the most recent and complete version of the guideline, go online to NCCN.org. NCCN makes no warranties of any kind whatsoever regarding their content, use or application and disclaims any responsibility for their application or use in any way.
   Google Scholar
• Won KA , SpruckC. Triple negative breast cancer therapy: current and future perspectives (Review). Int. J. Oncol.57(6), 1245–1261 (2020).
   PubMed Web of Science ®Google Scholar
• Li X , YangJ, PengLet al. Triple-negative breast cancer has worse overall survival and cause-specific survival than non-triple-negative breast cancer. Breast Cancer Res. Treat.161(2), 279–287 (2017).
   PubMed Web of Science ®Google Scholar
• Savci-Heijink CD , HalfwerkH, HooijerGK, HorlingsHM, WesselingJ, VanDe Vijver MJ. Retrospective analysis of metastatic behaviour of breast cancer subtypes. Breast Cancer Res. Treat.150(3), 547–557 (2015).
   PubMed Web of Science ®Google Scholar
• National Cancer Institute. Surveillance, Epidemiology, and End Results Program . Cancer stat facts: female breast cancer subtypes. https://seer.cancer.gov/statfacts/html/breast-subtypes.html ( 2 January 2023).
   Google Scholar
• American Cancer Society . Breast Cancer Facts & Figures 2019–2020. www.cancer.org/content/dam/cancer-org/research/cancer-facts-and-statistics/breast-cancer-facts-and-figures/breast-cancer-facts-and-figures-2019-2020.pdf ( 2 January 2023).
   Google Scholar
• Gilead Sciences, Inc . Drug Label for Trodelvy. www.gilead.com/-/media/files/pdfs/medicines/oncology/trodelvy/trodelvy_pi.pdf ( 2 January 2023).
   Google Scholar
• eCQI . QDM - quality data model. https://ecqi.healthit.gov/qdm ( 2 January 2023).
   Google Scholar
• Paracha N , ReyesA, DierasV, KropI, PivotX, UrruticoecheaA. Evaluating the clinical effectiveness and safety of various HER2-targeted regimens after prior taxane/trastuzumab in patients with previously treated, unresectable, or metastatic HER2-positive breast cancer: a systematic review and network meta-analysis. Breast Cancer Res. Treat.180(3), 597–609 (2020).
   PubMed Web of Science ®Google Scholar
• Miles DW , DierasV, CortesJ, DuenneAA, YiJ, O’shaughnessyJ. First-line bevacizumab in combination with chemotherapy for HER2-negative metastatic breast cancer: pooled and subgroup analyses of data from 2447 patients. Ann. Oncol.24(11), 2773–2780 (2013).
   PubMed Web of Science ®Google Scholar
• Pandy JGP , Balolong-GarciaJC, Cruz-OrdinarioMVB, QueFVF. Triple negative breast cancer and platinum-based systemic treatment: a meta-analysis and systematic review. BMC Cancer19(1), 1065 (2019).
   PubMed Web of Science ®Google Scholar
• Li CH , KarantzaV, AktanG, LalaM. Current treatment landscape for patients with locally recurrent inoperable or metastatic triple-negative breast cancer: a systematic literature review. Breast Cancer Res.21(1), 143 (2019).
   PubMed Web of Science ®Google Scholar
• Wu Y , ZhangY, PiH, ShengY. Current therapeutic progress of CDK4/6 inhibitors in breast cancer. Cancer Manag. Res.12, 3477–3487 (2020).
   PubMed Web of Science ®Google Scholar
• Bauer KR , BrownM, CressRD, PariseCA, CaggianoV. Descriptive analysis of estrogen receptor (ER)-negative, progesterone receptor (PR)-negative, and HER2-negative invasive breast cancer, the so-called triple-negative phenotype: a population-based study from the California cancer Registry. Cancer109(9), 1721–1728 (2007).
   PubMed Web of Science ®Google Scholar
• Rossi V , BerchiallaP, GiannarelliDet al. Should all patients with HR-positive HER2-negative metastatic breast cancer receive CDK 4/6 inhibitor as first-line based therapy? a network meta-analysis of data from the PALOMA 2, MONALEESA 2, MONALEESA 7, MONARCH 3, FALCON, SWOG and FACT trials. Cancers (Basel)11(11), 1661 (2019).
   PubMed Web of Science ®Google Scholar
• Grinda T , AntoineA, JacotWet al. Evolution of overall survival and receipt of new therapies by subtype among 20 446 metastatic breast cancer patients in the 2008–2017 ESME cohort. ESMO Open6(3), 100114 (2021).
   PubMed Web of Science ®Google Scholar
• Agarwal G , NandaG, LalPet al. Outcomes of triple-negative breast cancers (TNBC) compared with non-TNBC: does the survival vary for all stages? World J. Surg. 40(6), 1362–1372 (2016).
   PubMed Web of Science ®Google Scholar
• Dietze EC , SistrunkC, Miranda-CarboniG, O’reganR, SeewaldtVL. Triple-negative breast cancer in African–American women: disparities versus biology. Nat. Rev. Cancer15(4), 248–254 (2015).
   PubMed Web of Science ®Google Scholar
• Kumar P , AggarwalR. An overview of triple-negative breast cancer. Arch. Gynecol. Obstet.293(2), 247–269 (2016).
   PubMed Web of Science ®Google Scholar
• Murphy JD , NelsonLM, ChangDT, MellLK, LeQT. Patterns of care in palliative radiotherapy: a population-based study. J. oncology practice/ASCO9(5), e220–227 (2013).
   PubMedGoogle Scholar
• Deluche E , AntoineA, BachelotTet al. Contemporary outcomes of metastatic breast cancer among 22,000 women from the multicentre ESME cohort 2008–2016. Eur. J. Cancer129, 60–70 (2020).
   PubMed Web of Science ®Google Scholar
• Lindman H , WiklundF, AndersenKK. Long-term treatment patterns and survival in metastatic breast cancer by intrinsic subtypes – an observational cohort study in Sweden. BMC Cancer22(1), 1006 (2022).
   PubMed Web of Science ®Google Scholar
• Li Y , WangS, YangW, LiuH. Prognostic significance of molecular subtype, metastatic site and primary tumor surgery for survival in primary metastatic breast cancer: A SEER-based study. Medicine (Baltimore)100(27), e26619 (2021).
   PubMed Web of Science ®Google Scholar
• Tao L , ChuL, WangLIet al. Occurrence and outcome of de novo metastatic breast cancer by subtype in a large, diverse population. Cancer causes & control: CCC27(9), 1127–1138 (2016).
   PubMed Web of Science ®Google Scholar
• File DM , PascualT, DealAMet al. Clinical subtype, treatment response, and survival in de novo and recurrent metastatic breast cancer. Breast Cancer Res. Treat.196(1), 153–162 (2022).
   PubMed Web of Science ®Google Scholar
• Arora S , NarayanP, OsgoodCLet al. U.S. FDA drug approvals for breast cancer: a decade in review. Clin. Cancer Res.28(6), 1072–1086 (2022).
   PubMed Web of Science ®Google Scholar
• Yardley DA , KaufmanPA, BrufskyAet al. Treatment patterns and clinical outcomes for patients with de novo versus recurrent HER2-positive metastatic breast cancer. Breast Cancer Res. Treat.145(3), 725–734 (2014).
   PubMed Web of Science ®Google Scholar
• Cobleigh M , YardleyDA, BrufskyAMet al. Baseline characteristics, treatment patterns, and outcomes in patients with HER2-positive metastatic breast cancer by hormone receptor status from SystHERs. Clin. Cancer Res.26(5), 1105–1113 (2020).
   PubMed Web of Science ®Google Scholar
• Annonay M , GauquelinL, GeissRet al. Treatment and outcomes of older versus younger women with HER2-positive metastatic breast cancer in the real-world national ESME database. Breast60, 138–146 (2021).
   PubMed Web of Science ®Google Scholar